Boston, MA 03/04/2014 (wallstreetpr) – Akorn, Inc. (NASDAQ:AKRX) the pharma company which has a multiple sector presence in the industry has reported some poor performance numbers of the quarter past. The result was a downward spiral on the stock market. As news of this generic pharmaceutical broke news, the stock lost the rally, falling by nearly 18%, over the poor fourth quarter performance for the past fiscal.
Akorn, Inc. (NASDAQ:AKRX) passed through a difficult quarter, with less than comforting margins. And this is cause of worry for investors and the company alike.
Revenue earningspass estimates
Though the revenue growth was 19% valued at $85 million, it remains a weak point to say the company is on safe ground. The past revenue growth was due to the range of products Akorn, Inc. (NASDAQ:AKRX) launched in later half of 2012, extending further into 2013. Therefore some internal balancing of funds resulted in rise in profits. Though, the rise remained modest at $0.14 per share, in comparison to the per share rise in $0.13 about a year ago, the gross also saw a dip by over 340 basis points. The end result is in the region of 55.3%.
Akorn, Inc. (NASDAQ:AKRX) did surpass estimations in terms of the revenues. Where Wall Street expected AKRX to pull-in $83.4 million, the company moved forward with $85 million and the EPS by over $0.14.
Forward looking
Akorn, Inc. (NASDAQ:AKRX) has also posted that the fiscal 2014 will remain dicey for this pharma company which products spanning the ophthalmic to hospital indications as well as injectable pharmaceutical products as well. With the guidance for 2014 pointed between $540 million and $560 million as per company reports is much higher than the consensus based estimates the company can offer at $501 million. The EPS too is $0.86 for the consensus estimates while the reported EPS is $0.76 and $0.79.
